CROMSOURCE, an international full service contract research organization (CRO), today announced the official opening of new office premises in Paris, France.
CROMSOURCE, an international full service contract research organization (CRO), today announced the official opening of new office premises in Paris, France.
‘CROMSOURCE continues to grow successfully as a result of our unique commitment to deliver our clients’ projects on time, on budget and to the highest quality’, noted Oriana Zerbini, CEO of CROMSOURCE. ‘As a result we needed to increase our presence in France, and I am delighted to announce that we have done this through expansion of our team and the opening of new office premises.’
‘With more than 33% of international phase II and III studies being performed here, France is a key strategic country for CROMSOURCE’, said Christian Milla, Global Head of the Medical Division and Director of Operations, France. Christian is based in the new offices, which are located on the Left Bank area of Paris, close to the University of Sciences and the Paris Biopark. ‘We have been growing our activity here year on year, and we look forward to further growth in this region in years to come. With our intense client focus, comprehensive service portfolio and international reach we are a perfect development partner for the vibrant life sciences industry in France. Being on the French Ministry of Research (FMR) list of approved CROs also means that many of our clients can claim significant tax credits for R&D activities executed by CROMSOURCE on their behalf.’
Margherita Mosconi, Director of Client Project Development, added ‘There is a high demand in France from smaller biopharmaceutical and medical technology companies for knowledgeable partners who can support them and keep within timelines and budgets. These clients appreciate the CROMSOURCE philosophy of acting as an expert addition to their team. We leverage our expertise to propose the optimal approach to each of their projects. Uniquely, we then guarantee to deliver the plan to the highest quality, on time and on budget.’
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.